TD Cowen cuts Alignment Healthcare stock price target on EBITDA concerns

TD Cowen cut its price target on Alignment Healthcare to $12 from $21 and reduced adjusted EBITDA estimates to $140 million, $196 million and $255 million for 2026–2028, respectively, from $156 million, $216 million and $280 million. The firm cited expected inpatient and skilled-nursing utilization pressure and unfavorable claims development; the stock was $8.13, down 11% over the past week and 63% over six months. Other firms have also cut targets or ratings, citing Medicare star-rating declines and cost pressures.

Analysis

The key issue is not a one-quarter EBITDA haircut; it is whether utilization and claims development expose a weaker earnings base just as lower star ratings constrain the ability to compete for members. If elevated inpatient and skilled-nursing use persists, medical-cost pressure can compound with weaker plan economics and enrollment retention, making current-year estimate cuts a poor proxy for the full impact. Conversely, a rapid claims normalization would support the view that the current reset is largely timing-related.

The star-rating effects are a separate, slower-moving risk: they can affect plan competitiveness and economics across future benefit years, so a rebound in quarterly utilization alone would not resolve the thesis. Larger Medicare Advantage operators, including UnitedHealth and Humana, could be relative beneficiaries if members shift toward better-rated alternatives, although sector-wide utilization or policy pressure would limit that substitution benefit.

The “value per Medicare Advantage life” comparison is not a dependable floor: it abstracts from the quality and durability of those lives’ earnings and the cost of servicing them. The immediate reaction may already reflect substantial skepticism after the stock’s steep decline; the more important 1–3 month test is claims development and management’s ability to substantiate a return to improving economics. Over 6–18 months, rating-related competitiveness and retention matter more. The thesis is falsified by sustained claims normalization, stable enrollment, and evidence that future-plan economics are not materially impaired. No exposure to BAC follows: Bank of America Securities’ analyst commentary is not a company-specific catalyst for Bank of America Corporation.

Key Decisions for Investors

• Keep ALHC underweight versus diversified managed-care exposure; avoid treating the analyst valuation multiple or acquisition-per-life range as a downside floor.
• Do not add to ALHC solely because the shares have fallen sharply. Reassess after the next earnings update for medical-cost/utilization trends, unfavorable claims development, enrollment and management’s quantified outlook.
• Watch for a tactical relative-value opportunity—short ALHC against a diversified managed-care basket—only if claims deterioration persists or guidance weakens; close or avoid the position if claims normalize and enrollment remains stable. Size for substantial company-specific volatility.
• No trade in BAC: the article describes Bank of America Securities research, not a change in Bank of America Corporation’s fundamentals.